Back to top

Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Targets Fatty Liver Disease With New Phase 2a Stud...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Regeneron Pharmaceuticals, Inc. (REGN)